Zydus Lifesciences Share Price (ZYDUSLIFE)
Check the latest share price of Zydus Lifesciences, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 15 Jul 2025
NSE
🔔 Approval Alert
Zydus Lifesciences receives USFDA approval for Celecoxib capsules, expanding its U.S. generics portfolio with annual sales of approximately $122.6 million.
Zydus Lifesciences Stock Performance
Get live Zydus Lifesciences share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹961.5Day's Price Range₹975.7552 Week's Low
52 Week's High
₹79552-Week Price Range₹1,324.3
| Returns % | |
| 1 Month Return | -0.61 % |
| 3 Month Return | + 9.66 % |
| 1 Year Return | -18.48 % |
| 3 Year Return | + 161.07 % |
| 5 Year Return | + 173.15 % |
| Market Stats | |
| Previous Close | ₹968.45 |
| Open | ₹971.00 |
| Volume | 5.53L |
| Upper Circuit | ₹1,065.25 |
| Lower Circuit | ₹871.60 |
Zydus Lifesciences Fundamentals & Key Indicators
Check Zydus Lifesciences market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹97,448.73 Cr
Return on Equity (ROE)
23.45
PE Ratio (TTM)
21.53
Return on capital employed (ROCE)
22.73
Industry PE ratio
51.74
Beta (LTM)
0.78
P/B Ratio
6.43
Dividend Yield
0.3
PEG Ratio
3.15
Quarterly Earnings Growth YOY
1.61
EPS (TTM)
38.31
Sector
Pharmaceuticals
Book Value
197.11
Technical Analysis
Bullish
View Technical Analysis
How to invest in Zydus Lifesciences?
Investing in Zydus Lifesciences is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Zydus Lifesciences or ZYDUSLIFE on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Zydus Lifesciences or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Zydus Lifesciences with just a few clicks!
Zydus Lifesciences Stock's Interest Amongst Investors
Zydus Lifesciences Valuation
Track how Zydus Lifesciences P/E has moved over time to understand its valuation trends.
Zydus Lifesciences in the last 5 years
Lowest (7.34x)
March 7, 2022
Today (21.53x)
July 14, 2025
Industry (51.74x)
July 14, 2025
Highest (34.62x)
March 26, 2024
Today’s Price to Earnings Ratio: 21.53x
Zydus Lifesciences Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Zydus Lifesciences.
based on 30 analysts
40.00%
Buy
36.67%
Hold
23.33%
Sell
40% of analysts recommend a 'HOLD' rating for Zydus Lifesciences. Average target price of ₹967.2
Source: S&P Global Market Intelligence
Zydus Lifesciences Share Price Target
Get share price movements and forecasts by analysts on Zydus Lifesciences.
Zydus Lifesciences price forecast by 30 analysts
Downside of-0.13%
High
₹1150
Target
₹967.20
Low
₹794
Zydus Lifesciences target price ₹967.2, a slight downside of -0.13% compared to current price of ₹967.65. According to 30 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Zydus Lifesciences revenue growth forecast
Expected growth rate Q1, FY2027:32.52%
Forecast
Actual
Including amortisation and stock based compensations
Zydus Lifesciences EPS growth forecast
EPS estimate Q1, FY2027:9.46%
Forecast
Actual
Source: S&P Global Market Intelligence
Zydus Lifesciences Financial Results
Get the annual and quarterly financial summary of Zydus Lifesciences, including revenue, profit, loss and more.
Indices Featuring Zydus Lifesciences Stock
Check stock indices that include Zydus Lifesciences.
Zydus Lifesciences Earnings and Dividends
View detailed summary of the earnings and dividend history of Zydus Lifesciences.
Zydus Lifesciences Ltd Earnings Results
Zydus Lifesciences Ltd’s net profit fell -0.96% since last year same period to ₹1,170.90Cr in the Q4 2024-2025. On a quarterly growth basis, Zydus Lifesciences Ltd has generated 14.4% jump in its net profits since last 3-months.
Read More about Earnings ResultsZydus Lifesciences Ltd Dividends May,2024
In the quarter ending March 2024, Zydus Lifesciences Ltd has declared dividend of ₹3.00 - translating a dividend yield of 0.93%.
Read More about Dividends
Zydus Lifesciences Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Zydus Lifesciences.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 74.99% | 0.00 | |
| Foreign Institutions | 7.32% | 0.00 | |
| Mutual Funds | 6.36% | 0.00 | |
| Retail Investors | 6.68% | 0.00 | |
| Others | 4.65% | 0.00 |
Zydus Lifesciences vs Peers
Compare market cap, revenue, PE, and other key metrics of Zydus Lifesciences with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| HOLD | 97,448.73 | 34.63% | 0.64 | 3,854 | 19,547 | |
| BUY | 13,647.58 | -4.65% | 0.52 | 413 | 2,013 | |
| BUY | 66,714.97 | 7.11% | 0.56 | 3,168 | 29,001 | |
| BUY | 72,876.88 | 25.09% | 0.53 | NA | NA | |
| BUY | 54,004.95 | 21.75% | 0.56 | 927 | 3,749 |
Zydus Lifesciences News & Key Events
Latest news and events in one place to help you make informed investing decisions in Zydus Lifesciences.
Zydus Lifesciences Secures USFDA Approval for Celecoxib - 15 Jul, 2025
Zydus Lifesciences has received final USFDA approval for Celecoxib Capsules, a painkiller used for various inflammatory conditions, with annual U.S. sales of $122.6 million. This approval adds to Zydus's growing generics portfolio, bringing total approvals to 428 out of 492 applications filed since FY 2003-04.Jefferies Maintains Buy Rating for Zydus Lifesciences - 08 Jul, 2025
Jefferies has reaffirmed its Buy rating on Zydus Lifesciences, setting a target price of ₹1,150, supported by a strong growth outlook for FY26 and management's guidance for double-digit revenue growth and margins above 26%. The brokerage believes Zydus is well-positioned despite challenges in the market.Zydus Lifesciences Addresses Lost Share Certificate - 02 Jul, 2025
Zydus Lifesciences Limited has issued a notice regarding a lost share certificate by a shareholder, cautioning against transactions involving it. A duplicate will be issued if no objections arise within seven days, safeguarding shareholder interests.Zydus Lifesciences Acquires Majority Stake in Amplitude Surgical - 01 Jul, 2025
Zydus Lifesciences announced the acquisition of an 85.6% stake in France-based Amplitude Surgical for Euro 256.8 million (approximately Rs 2,380 crore), reflecting a strong enterprise value to sales ratio.Zydus Lifesciences Reports Mixed Financial Results - 24 Jun, 2025
Zydus Lifesciences reported a 17.96% increase in net sales to Rs 6,527.90 crore for March 2025, but net profit fell by 6.03%. EBITDA rose by 23.46%, while EPS slightly decreased. The stock has underperformed, with -2.18% returns over the last 6 months and -11.87% over the last year.Zydus Lifesciences' FDA Inspection Concludes Positively - 18 Jun, 2025
Zydus Lifesciences announced the successful conclusion of a USFDA inspection at its oncology injectable facility, receiving two minor observations, none related to data integrity. The company is committed to addressing these observations promptly.Zydus Lifesciences Appoints New Managing Director - 16 Jun, 2025
Zydus Lifesciences announced the appointment of Swati Dalal as Managing Director of Zydus Healthcare, effective June 16, 2025. The company reported a slight decline in net profit despite a significant revenue increase. Shares fell by 0.51% to Rs 970.
Insights on Zydus Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 6.32% to 6.36% in Mar 2025 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 911.2 Cr → 1.17K Cr (in ₹), with an average increase of 11.8% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ZYDUSLIFE has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Price Rise
In the last 3 years, ZYDUSLIFE stock has moved up by 161.1%
- POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 74.98% to 74.99% in Mar 2025 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 5.30K Cr → 6.60K Cr (in ₹), with an average increase of 9.9% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 48.2% return, outperforming this stock by 66.6%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 7.53% to 7.32% in Mar 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.84% to 6.68% in Mar 2025 quarter
About Zydus Lifesciences
The company has a strong presence in the global market and is known for its high-quality pharmaceutical products. It manufactures a wide range of generic and specialty drugs, including cardiovascular, anti-infective, anti-diabetic, and oncology medicines. Zydus also produces over-the-counter products and nutritional supplements. Some of its top products include Zetia, Atorvastatin, and Metformin.
Zydus Lifesciences Ltd is also known for its popular brands, such as Cadila, Nutralite, and Zydus Wellness. The company has a strong presence in the Indian market, with its products being sold in more than 20,000 stores across the country. It also exports its products to over 100 countries worldwide.
Revenue: ₹6,290.20Cr as on March 2025 (Q4 FY25)
Net Profit: ₹1,248.80Cr as on March 2025 (Q4 FY25)
Listing date: 18 Apr, 2000
Chairperson Name: Pankaj R Patel
| Organisation | Zydus Lifesciences Ltd |
| Headquarters | Ahmedabad |
| Industry | Pharmaceuticals |
| CEO | Pankaj R Patel |
| E-voting on shares | Click here to vote |
Mutual Funds that own Zydus Lifesciences
Check out the Mutual Funds with significant holdings in Zydus Lifesciences.
FAQs
What is Zydus Lifesciences share price today?
Zydus Lifesciences share price today stands at ₹967.65, Open: ₹971, Previous Close: ₹968.45, High: ₹975.75, Low: ₹961.5, 52 Week High: ₹1324.3, 52 Week Low: ₹795.
What is today's traded volume of Zydus Lifesciences?
Today's traded volume of Zydus Lifesciences is 5.53L. Which means that 5.53L shares of Zydus Lifesciences were bought and sold on the stock market during today's trading session.
What is Zydus Lifesciences's market cap today?
Today's market capitalisation of Zydus Lifesciences is ₹97,448.73 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Zydus Lifesciences?
Zydus Lifesciences’s 52 week high is ₹1324.3 and 52 week low is ₹795. The current share price of Zydus Lifesciences is ₹967.65, which is -26.93% down from its 52 week high and 21.72% up from its 52 week low.